Insider Selling: Precigen (NASDAQ:PGEN) CFO Sells $948,002.37 in Stock

Posted by Francis Steltz on Jul 4th, 2026

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) CFO Harry Jr. Thomasian sold 171,429 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $5.53, for a total value of $948,002.37. Following the completion of the transaction, the chief financial officer owned 354,535 shares of the company’s stock, valued at $1,960,578.55. This represents a 32.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Harry Jr. Thomasian also recently made the following trade(s):

On Monday, June 29th, Harry Jr. Thomasian sold 28,571 shares of Precigen stock. The stock was sold at an average price of $5.78, for a total transaction of $165,140.38.
On Thursday, May 28th, Harry Jr. Thomasian sold 41,884 shares of Precigen stock. The shares were sold at an average price of $4.36, for a total transaction of $182,614.24.

Precigen Stock Performance

Shares of PGEN opened at $5.64 on Friday. The firm has a market cap of $2.01 billion, a P/E ratio of -4.78 and a beta of 1.00. Precigen, Inc. has a twelve month low of $1.47 and a twelve month high of $6.04. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82. The firm’s 50 day moving average price is $4.49 and its two-hundred day moving average price is $4.25.

Precigen (NASDAQ:PGEN – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.01. Precigen had a negative net margin of 646.99% and a positive return on equity of 717.50%. The company had revenue of $23.25 million during the quarter, compared to the consensus estimate of $20.81 million. On average, analysts forecast that Precigen, Inc. will post -0.02 EPS for the current fiscal year.

Institutional Investors Weigh In On Precigen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State Street Corp lifted its position in Precigen by 141.1% during the 4th quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock worth $45,248,000 after buying an additional 6,335,033 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Precigen by 15.9% in the 4th quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock valued at $18,653,000 after acquiring an additional 613,340 shares in the last quarter. Occam Crest Management LP grew its holdings in shares of Precigen by 29.6% in the 4th quarter. Occam Crest Management LP now owns 3,501,739 shares of the biotechnology company’s stock valued at $14,637,000 after acquiring an additional 799,339 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in shares of Precigen in the fourth quarter valued at about $12,540,000. Finally, Bank of America Corp DE increased its position in shares of Precigen by 201.1% in the third quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock valued at $8,245,000 after acquiring an additional 1,673,731 shares during the last quarter. 33.51% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on PGEN shares. HC Wainwright lifted their price target on Precigen from $11.00 to $14.00 and gave the company a “buy” rating in a research note on Thursday, May 28th. Wall Street Zen cut Precigen from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Tuesday, April 21st. Citizens Jmp lifted their target price on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Finally, Citigroup restated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $12.50.

Get Our Latest Stock Analysis on Precigen

Precigen Company Profile

(Get Free Report)

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.